Gerd Zettlmeissl Asit Biotech
Gerd Zettlmeissl, © TuBerculosis Vaccine Initiative

Asit biotech: Expertise in vaccines

Belgian clinical-stage immunotherapy developer  Asit biotech has appointed Gerd Zettlmeissl as its new Chairman of the Board. Zettlmeissl has been independent director of the company since 2011. 

 Before joining Asit biotech, he was CEO of Austrian company Intercell AG – which in 2013 merged with French company Vivalis create European vaccine and antibody leader Valneva. Zettlmeissl holds a doctoral degree in biochemistry from the University of Regensburg in Germany and did a post-doctoral fellowship in virology at the Institut Pasteur in Paris. Since 1985, Zettlmeissl has held various R&D and managerial positions at a number of international pharmaceutical companies, among others Managing Director of German vaccine company Chiron Behring.

 

In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Zettlmeissl currently serves as non-executive director of Aeras, (USA). Until early 2015, he was chairman of GlycoVaxyn (Switzerland), an innovative vaccine company acquired by GlaxoSmithKline.

Erstwhile Asit biotech Chairman Béatrice De Vos has stepped down “to focus on new projects”.

Gerd Zettlmeissl, says: “I am particularly enthusiastic about being able to continue contributing, as Chairman, to the development and future marketing of the next generation of immunotherapy products in order to meet the needs of patients who are seeking significantly less restrictive treatments. I would also like to thank all of the Board’s members, and the ASIT biotech teams, for the trust they have put in me. I firmly believe in the Company’s prospects, and pledge to make the most of my substantial experience in the global development of new therapeutic solutions.

Thierry Legon, CEO of ASIT biotech, adds: “We would like to thank Béatrice De Vos for her remarkable contribution to ASIT biotech’s clinical progress since 2013, the year she was appointed Chairwoman. Her availability and her considerable expertise in terms of the clinical development of drug candidates have been valuable assets for the Company and the success of its IPO in May 2016. We respect her decision, and wish her every success and fulfillment in her future professional and personal projects. Gerd Zettlmeissl’s arrival as Chairman will ensure continuity in the excellence of our governance and the pertinence of ASIT biotech’s strategy, which I firmly believe will enable us to successfully meet the many challenges that await us in 2017 on which we are actively working.

Here's To Your Health
We're reporting in on the latest in health news, medical research, insurance coverage, plus managing your health and the health of the people you love.
We respect your privacy